Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis
Fibrosis, Liver
About this trial
This is an interventional diagnostic trial for Fibrosis, Liver focused on measuring Hepatitis B, Hepatitis C, Fibrosis, Liver, Magnetic Resonance Imaging
Eligibility Criteria
Inclusion Criteria:
- All naive patients with chronic hepatitis B or C infection who undergo liver biopsy examination for evaluating candidates for antiviral therapy will be invited to participate into this study
Exclusion Criteria:
- Other cause of chronic liver disease
- Contraindication for liver biopsy
- Contraindication for magnetic resonance imaging
Sites / Locations
- Faculty of Medicine Siriraj Hospital
Arms of the Study
Arm 1
Other
Diffusion-weighted imaging
Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.